

OMEGA-3 FATTY ACIDS AND CARDIOVASCULAR HEALTH

According to the American Heart Association, approximately one in three deaths in the U.S. result from cardiovascular disease (CVD), with more than 2,100 people dying from it each day.¹ Although the treatment of CVD has improved markedly in the last decade, other factors such as hypertension, smoking, type 2 diabetes, physical inactivity and poor diet contribute substantially to an individual's chance of CVD mortality. Because diet contributes importantly to CVD, high blood pressure, diabetes and obesity and can be improved, this paper focuses on the contribution of dietary long-chain omega-3 polyunsaturated fatty acids (omega-3 PUFAs) to reducing the risk of CVD.

Long-chain omega-3 PUFAs come primarily from seafood or marine algae and consist mainly of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), with small amounts of docosapentaenoic acid. They are chiefly responsible for the association between regular fish consumption and a significantly lower risk of dying from CVD or coronary heart disease (CHD) in older adults,^{2,3} in patients who survived a myocardial infarction (heart attack),⁴ those on hemodialysis⁵ and other patients.^{6,7} Some recent clinical trials, however, reported no significant reduction in CVD mortality in patients at high risk of CVD who consumed EPA and DHA.⁸⁻¹⁰ Reasons for the discrepancy between earlier trials and more recent ones may relate to the lower risk of mortality in patients now receiving state-of-the-art medical care,⁷ insufficient statistical power in the study design¹¹ and a background of increased consumption of fish or omega-3 supplements.¹²⁻¹⁴ Further, the use of several combined endpoints, such as fatal and nonfatal cardiac events, to evaluate the effect of omega-3 PUFAs increases the likelihood of observing no significant effect.^{15,16} In contrast to studies claiming no benefit from omega-3 PUFAs in reducing the risk of heart disease mortality, other recent trials have documented a significantly lower risk of CVD mortality with higher consumption or blood levels of EPA and DHA.^{2,17,18} Providing greater amounts of omega-3 PUFAs in CVD patients also warrants additional investigation. Evaluation of controversial studies requires an overview of the big picture before rejecting decades of credible findings and the more sophisticated understanding of CVD we now have.^{15,19}

Omega-3 PUFAs, especially EPA, may be beneficial for individuals with heart failure. In this condition, the heart's ability to pump blood is impaired, leaving the tissues short of oxygen and a person feeling tired and short of breath. Heart failure affects more than 5 million Americans above the age of 20 years and carries a high risk of mortality.²⁰ Approximately half of patients with heart failure die within five years of diagnosis.²¹ However, greater consumption of fish or omega-3 PUFAs or higher levels of EPA in the blood are associated with a lower risk of heart failure and reduced mortality from it.²²⁻²⁴ Treatment of heart failure patients with omega-3 PUFAs may also improve ventricular function.²⁵⁻²⁷ In another study, survivors of acute myocardial infarction (heart attack) who were treated with both a statin and omega-3 PUFAs experienced a significantly longer survival without heart failure compared with patients who received only the statin medication.²⁸ Others reported that patients with chronic heart failure and major depressive disorder who had higher plasma levels of omega-3 PUFAs or EPA had significantly longer survival compared with patients with the lowest levels of omega-3 PUFAs.²⁹ A review and meta-analysis of seven clinical trials in patients with heart failure concluded that fish oils are associated with improved cardiac performance, remodeling and functional capacity.³⁰

Consumption of omega-3 PUFAs from marine sources has antithrombotic and anti-inflammatory effects and may have antiarrhythmic effects.^{31,32} These fatty acids inhibit platelet aggregation and decrease thrombin formation, which discourages artery-blocking blood clot formation.³³⁻³⁵ However, the ability of omega-3 PUFAs to increase the time for blood to clot has led to concerns about the risk of increased bleeding. A recent investigation of this issue concluded that because of their multiple beneficial effects on hemostasis, there was no need to stop consuming omega-3 PUFAs prior to surgery or when consuming other agents that control blood clotting.³⁶ In addition, the consumption of omega-3 PUFAs is associated with increased heart rate variability³⁷ and lower heart rate at rest, during stress and in myocardial ischemia.^{38,39} These effects contribute to cardioprotection. Other important vascular effects of omega-3 PUFAs include a modest reduction in blood pressure,⁴⁰⁻⁴² increased dilation of the coronary arteries⁴³ and improved endothelial function.⁴⁴

The anti-inflammatory effects of marine omega-3 PUFAs are being intensely investigated in healthy individuals and those with various clinical conditions. Inflammation underlies the major chronic conditions, including CVD, type 2 diabetes, metabolic syndrome, obesity and many autoimmune diseases, namely rheumatoid arthritis, asthma, colitis, psoriasis and some allergies. In fact, inflammation is the link between insulin resistance, obesity and type 2 diabetes, each of which increases the risk of CVD.⁴⁵ Atherosclerosis—the accumulation of lipids, immune cells and other substances as plaque in the arteries—contributes to and aggravates CVD and reducing the inflammation associated with it has become the target of medical therapies.^{45,46} Through their effects on the endothelial cells lining the arteries, various immune cells and gene expression, omega-3 PUFAs reduce the excessive inflammatory activity observed in CVD.^{44,47} Relatively recently, a new class of omega-3 PUFA derivatives has shown potent ability to limit and terminate overactive inflammatory responses. These agents include resolvins, protectins, lipoxins and maresins.⁴⁸

One of the most important and consistent effects of omega-3 PUFAs is the reduction of blood triglyceride levels.⁴⁸ Hypertriglyceridemia occurs frequently in type 2 diabetes, obesity and several types of dyslipidemia and increases the risk of CVD by as much as 25%.⁴⁹ Very high levels of triglycerides increase the risk of pancreatitis as well. The triglyceride-lowering effect of omega-3 PUFAs is observed in individuals with normal blood lipid levels, but is dramatic in those with elevated triglycerides.^{50,51} Omega-3 PUFAs may be used alone or in conjunction with other therapies for the treatment of elevated triglycerides and have the advantage of minimal, if any, side effects.⁵²

This article has highlighted some of the main physiologic benefits of omega-3 PUFA consumption in CVD. Other effects beyond the scope of this paper include increased adiponectin levels, which are associated with increased fatty acid oxidation, improved insulin sensitivity and adipocyte function;⁵³ reduced oxidative stress;^{54,55} increased plaque stability;⁵⁶ and changes in membrane structure, signaling proteins and gene expression, all of which contribute to the ways omega-3 PUFAs protect cardiovascular health and extend life.²

References

1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Judd SE, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Mackey RH, Magid DJ, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER, 3rd, Moy CS, Mussolino ME, Neumar RW, Nichol G, Pandey DK, Paynter NP, Reeves MJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Wong ND, Woo D, Turner MB. Executive summary: heart disease and stroke statistics--2014 update: a report from the American Heart Association. *Circulation* 2014;129:399-410.
2. Mozaffarian D, Lemaitre RN, King IB, Song X, Huang H, Sacks FM, Rimm EB, Wang M, Siscovick DS. Plasma phospholipid long-chain omega-3 fatty acids and total and cause-specific mortality in older adults: a cohort study. *Ann Intern Med* 2013;158:515-525.
3. Chowdhury R, Stevens S, Gorman D, Pan A, Warnakula S, Chowdhury S, Ward H, Johnson L, Crowe F, Hu FB, Franco OH. Association between fish consumption, long chain omega 3 fatty acids, and risk of cerebrovascular disease: systematic review and meta-analysis. *BMJ* 2012;345:e6698.
4. GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-prevenzione trial. *Lancet* 1999;354:447-455.
5. Friedman AN, Yu Z, Tabbey R, Denski C, Tamez H, Wenger J, Thadhani R, Li Y, Watkins BA. Inverse relationship between long-chain n-3 fatty acids and risk of sudden cardiac death in patients starting hemodialysis. *Kidney international* 2013;83:1130-1135.
6. Trikalinos TA LJ, Moorthy D, Yu WW, Lau J, Lichtenstein AH, Chung M. Effects of Eicosapentanoic Acid and Docosahexanoic Acid on Mortality Across Diverse Settings: Systematic Review and Meta-Analysis of Randomized Trials and Prospective Cohorts: Nutritional Research Series, Vol. 4. Rockville, MD: Agency for Healthcare Research and Quality (US), 2012.
7. Kromhout D, de Goede, J. Update on cardiometabolic health effects of w-3 fatty acids. *Curr Opin Lipidol* 2014;25:85-90.
8. Galan P, Kesse-Guyot E, Czernichow S, Briancon S, Blacher J, Hercberg S. Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. *BMJ* 2010;341:c6273.
9. Kromhout D GE, Geleijnse JM; Alpha Omega Trial Group. n-3 fatty acids and cardiovascular events after myocardial infarction. *New England Journal of Medicine* 2010;363:2015-2026.
10. Rauch B SR, Schneider S, Diller F, Victor N, Gohlke H, Gottwik M, Steinbeck G, Del Castillo U, Sack R, Worth H, Katus H, Spitzer W, Sabin G, Senges J; OMEGA Study Group. OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. *Circulation* 2010;122:2152-2159.
11. Mozaffarian D, Wu JH. Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. *Journal of the American College of Cardiology* 2011;58:2047-2067.

12. Adams J, Sibbritt D, Lui CW, Broom A, Wardle J. {Omega}-3 fatty acid supplement use in the 45 and Up Study Cohort. *BMJ Open* 2013;3:pii: e002292.
13. The Risk and Prevention Study Collaborative Group. n-3 fatty acids in patients with multiple cardiovascular risk factors. *New England Journal of Medicine* 2013;368:1800-1808.
14. Kim HJ, Giovannucci E, Rosner B, Willett WC, Cho E. Longitudinal and secular trends in dietary supplement use: nurses' health study and health professionals follow-up study, 1986-2006. *Journal of the Academy of Nutrition and Dietetics* 2014;114:436-443.
15. Wu JH, Mozaffarian D. Omega-3 Fatty acids, atherosclerosis progression and cardiovascular outcomes in recent trials: new pieces in a complex puzzle. *Heart* 2014.
16. Rizos EC, Ntzani EE, Bika E, Kostapanos MS, Elisaf MS. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. *JAMA : The Journal of the American Medical Association* 2012;308:1024-1033.
17. Koh AS, Pan A, Wang R, Odegaard AO, Pereira MA, Yuan JM, Koh WP. The association between dietary omega-3 fatty acids and cardiovascular death: the Singapore Chinese Health Study. *European Journal of Preventive Cardiology* 2013.
18. de Oliveira Otto MC, Wu JH, Baylin A, Vaidya D, Rich SS, Tsai MY, Jacobs DR, Jr., Mozaffarian D. Circulating and dietary omega-3 and omega-6 polyunsaturated fatty acids and incidence of CVD in the Multi-Ethnic Study of Atherosclerosis. *J Am Heart Assoc* 2013;2:e000506.
19. Harris WS. Are n-3 fatty acids still cardioprotective? *Current Opinion in Clinical Nutrition and Metabolic care* 2013;16:141-149.
20. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Judd SE, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Mackey RH, Magid DJ, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER, 3rd, Moy CS, Mussolino ME, Neumar RW, Nichol G, Pandey DK, Paynter NP, Reeves MJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Wong ND, Woo D, Turner MB. Heart disease and stroke statistics--2014 update: a report from the american heart association. *Circulation* 2014;129:e28-e292.
21. Roger VL, Weston SA, Redfield MM, Hellermann-Homan JP, Killian J, Yawn BP, Jacobsen SJ. Trends in heart failure incidence and survival in a community-based population. *JAMA :The Journal of the American Medical Association* 2004;292:344-350.
22. Masson S, Marchioli R, Mozaffarian D, Bernasconi R, Milani V, Dragani L, Tacconi M, Marfisi RM, Borgese L, Cirrincione V, Febo O, Nicolis E, Maggioni AP, Tognoni G, Tavazzi L, Latini R. Plasma n-3 polyunsaturated fatty acids in chronic heart failure in the GISSI-Heart Failure Trial: relation with fish intake, circulating biomarkers, and mortality. *Am Heart J* 2013;165:208-215 e204.
23. Mozaffarian D, Lemaitre RN, King IB, Song X, Spiegelman D, Sacks FM, Rimm EB, Siscovick DS. Circulating long-chain omega-3 fatty acids and incidence of congestive heart failure in older adults: the cardiovascular health study: a cohort study. *Ann Intern Med* 2011;155:160-170.
24. Djousse L, Akinkuolie AO, Wu JH, Ding EL, Gaziano JM. Fish consumption, omega-3 fatty acids and risk of heart failure: a meta-analysis. *Clinical Nutrition* 2012;31:846-853.
25. Moertl D, Hammer A, Steiner S, Hutuleac R, Vonbank K, Berger R. Dose-dependent effects of omega-3-polyunsaturated fatty acids on systolic left ventricular function, endothelial function,

- and markers of inflammation in chronic heart failure of nonischemic origin: a double-blind, placebo-controlled, 3-arm study. *Am Heart J* 2011;161:915 e911-919.
- 26.** Ghio S, Scelsi L, Latini R, Masson S, Eleuteri E, Palvarini M, Vriz O, Pasotti M, Gorini M, Marchioli R, Maggioni A, Tavazzi L, investigators G-H. Effects of n-3 polyunsaturated fatty acids and of rosuvastatin on left ventricular function in chronic heart failure: a substudy of GISSI-HF trial. *European Journal of Heart Failure* 2010;12:1345-1353.
- 27.** Nodari S, Triggiani M, Manerba A, Milesi G, Dei Cas L. Effects of supplementation with polyunsaturated fatty acids in patients with heart failure. *Internal and Emergency Medicine* 2011;6 Suppl 1:37-44.
- 28.** Macchia A, Romero M, D'Ettorre A, Tognoni G, Mariani J. Exploratory analysis on the use of statins with or without n-3 PUFA and major events in patients discharged for acute myocardial infarction: an observational retrospective study. *PloS One* 2013;8:e62772.
- 29.** Jiang W, Oken H, Fiuzat M, Shaw LK, Martsberger C, Kuchibhatla M, Kaddurah-Daouk R, Steffens DC, Baillie R, Cuffe M, Krishnan R, O'Connor C, Investigators S-C. Plasma omega-3 polyunsaturated fatty acids and survival in patients with chronic heart failure and major depressive disorder. *Journal of Cardiovascular Translational Research* 2012;5:92-99.
- 30.** Xin W, Wei W, Li X. Effects of fish oil supplementation on cardiac function in chronic heart failure: a meta-analysis of randomised controlled trials. *Heart* 2012;98:1620-1625.
- 31.** Albert CM. Omega-3 fatty acids, ventricular arrhythmias, and sudden cardiac death: antiarrhythmic, proarrhythmic, or neither. *Circulation Arrhythmia and Electrophysiology* 2012;5:456-459.
- 32.** Billman GE. The effects of omega-3 polyunsaturated fatty acids on cardiac rhythm: a critical reassessment. *Pharmacology & Therapeutics* 2013;140:53-80.
- 33.** Gajos G, Zalewski J, Rostoff P, Nessler J, Piwowarska W, Undas A. Reduced thrombin formation and altered fibrin clot properties induced by polyunsaturated omega-3 fatty acids on top of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention (OMEGA-PCI clot). *Arteriosclerosis, Thrombosis, and Vascular Biology* 2011;31:1696-1702.
- 34.** Mori TA, Woodman RJ. The independent effects of eicosapentaenoic acid and docosahexaenoic acid on cardiovascular risk factors in humans. *Current Opinion in Clinical Nutrition and Metabolic Care* 2006;9:95-104.
- 35.** Larson MK, Tormoen GW, Weaver LJ, Luepke KJ, Patel IA, Hjelman CE, Ensz NM, McComas LS, McCarty OJ. Exogenous modification of platelet membranes with the omega-3 fatty acids EPA and DHA reduces platelet procoagulant activity and thrombus formation. *American Journal of Physiology Cell Physiology* 2013;304:C273-279.
- 36.** Wachira JK, Larson MK, Harris WS. n-3 Fatty acids affect haemostasis but do not increase the risk of bleeding: clinical observations and mechanistic insights. *Br J Nutr* 2014;1-11.
- 37.** Sauder KA, Skulas-Ray AC, Campbell TS, Johnson JA, Kris-Etherton PM, West SG. Effects of omega-3 fatty acid supplementation on heart rate variability at rest and during acute stress in adults with moderate hypertriglyceridemia. *Psychosomatic Medicine* 2013;75:382-389.
- 38.** Skulas-Ray AC, Kris-Etherton PM, Harris WS, West SG. Effects of marine-derived omega-3 fatty acids on systemic hemodynamics at rest and during stress: a dose-response study. *Annals of Behavioral Medicine : a publication of the Society of Behavioral Medicine* 2012;44:301-308.
- 39.** Billman GE, Harris WS. Effect of dietary omega-3 fatty acids on the heart rate and the heart rate variability responses to myocardial ischemia or submaximal exercise. *American Journal of Physiology Heart and Circulatory Physiology* 2011;300:H2288-2299.

40. Cabo J, Alonso R, Mata P. Omega-3 fatty acids and blood pressure. *Br J Nutr* 2012;107 Suppl 2:S195-200.
41. Mori TA. Omega-3 fatty acids and hypertension in humans. *Clinical and Experimental Pharmacology & Physiology* 2006;33:842-846.
42. Hoshi T, Wissuwa B, Tian Y, Tajima N, Xu R, Bauer M, Heinemann SH, Hou S. Omega-3 fatty acids lower blood pressure by directly activating large-conductance Ca(2)(+)-dependent K(+) channels. *Proceedings of the National Academy of Sciences of the United States of America* 2013;110:4816-4821.
43. Li X, Hong S, Li PL, Zhang Y. Docosahexanoic acid-induced coronary arterial dilation: actions of 17S-hydroxy docosahexanoic acid on K⁺ channel activity. *The Journal of Pharmacology and Experimental Therapeutics* 2011;336:891-899.
44. Wang Q, Liang X, Wang L, Lu X, Huang J, Cao J, Li H, Gu D. Effect of omega-3 fatty acids supplementation on endothelial function: a meta-analysis of randomized controlled trials. *Atherosclerosis* 2012;221:536-543.
45. Frostegard J. Immune Mechanisms in Atherosclerosis, Especially in Diabetes Type 2. *Frontiers in Endocrinology* 2013;4:162.
46. Witztum JL, Lichtman AH. The influence of innate and adaptive immune responses on atherosclerosis. *Annual Review of Pathology* 2014;9:73-102.
47. Myhrstad MC, Retterstol K, Telle-Hansen VH, Ottestad I, Halvorsen B, Holven KB, Ulven SM. Effect of marine n-3 fatty acids on circulating inflammatory markers in healthy subjects and subjects with cardiovascular risk factors. *Inflammation Research : official journal of the European Histamine Research Society [et al]* 2011;60:309-319.
48. Buckley CD, Gilroy DW, Serhan CN, Stockinger B, Tak PP. The resolution of inflammation. *Nature Reviews Immunology* 2013;13:59-66.
49. Liu J, Zeng FF, Liu ZM, Zhang CX, Ling WH, Chen YM. Effects of blood triglycerides on cardiovascular and all-cause mortality: a systematic review and meta-analysis of 61 prospective studies. *Lipids in Health and Disease* 2013;12:159.
50. Kastelein JJ, Maki KC, Susekov A, Ezhov M, Nordestgaard BG, Machielse BN, Kling D, Davidson MH. Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: The EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial. *Journal of Clinical Lipidology* 2014;8:94-106.
51. Tatsuno I, Saito Y, Kudou K, Ootake J. Long-term safety and efficacy of TAK-085 in Japanese subjects with hypertriglyceridemia undergoing lifestyle modification: the omega-3 fatty acids randomized long-term (ORL) study. *Journal of Clinical Lipidology* 2013;7:615-625.
52. Pirillo A, Catapano AL. Omega-3 polyunsaturated fatty acids in the treatment of atherogenic dyslipidemia. *Atherosclerosis Supplements* 2013;14:237-242.
53. Wu JH, Cahill LE, Mozaffarian D. Effect of fish oil on circulating adiponectin: a systematic review and meta-analysis of randomized controlled trials. *The Journal of Clinical Endocrinology and Metabolism* 2013;98:2451-2459.
54. Gladine C, Newman JW, Durand T, Pedersen TL, Galano JM, Demougeot C, Berdeaux O, Pujos-Guillot E, Mazur A, Comte B. Lipid Profiling following Intake of the Omega 3 Fatty Acid DHA Identifies the Peroxidized Metabolites F4-Neuroprostanes as the Best Predictors of Atherosclerosis Prevention. *PloS One* 2014;9:e89393.
55. Mas E, Woodman RJ, Burke V, Puddey IB, Beilin LJ, Durand T, Mori TA. The omega-3 fatty acids EPA and DHA decrease plasma F(2)-isoprostanes: Results from two placebo-controlled interventions. *Free Radical Research* 2010;44:983-990.

56. Cawood AL, Ding R, Napper FL, Young RH, Williams JA, Ward MJ, Gudmundsen O, Vige R, Payne SP, Ye S, Shearman CP, Gallagher PJ, Grimble RF, Calder PC. Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability. *Atherosclerosis* 2010;212:252-259.